These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 21095452)

  • 1. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
    Wüthrich RP; Serra AL
    Transplant Proc; 2009; 41(6 Suppl):S18-20. PubMed ID: 19651290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
    Ponticelli C; Locatelli F
    Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
    Serra AL; Wüthrich RP
    Praxis (Bern 1994); 2009 Dec; 98(25):1511-6. PubMed ID: 20013687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
    Soliman A; Zamil S; Lotfy A; Ismail E
    Transplant Proc; 2012 Dec; 44(10):2936-9. PubMed ID: 23195001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
    [No Abstract]   [Full Text] [Related]  

  • 14. mTOR inhibitors in polycystic kidney disease.
    Watnick T; Germino GG
    N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E; Cannella G
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
    Riegersperger M; Herkner H; Sunder-Plassmann G
    Trials; 2015 Apr; 16():182. PubMed ID: 25899445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.